Patents by Inventor Ozlem Tureci

Ozlem Tureci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES USEFUL IN CANCER DIAGNOSIS
    Publication number: 20200199221
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Application
    Filed: September 5, 2018
    Publication date: June 25, 2020
    Inventors: Rita MITNACHT-KRAUS, Stefan WÖLL, Korden WALTER, Özlem TÜRECI, Ugur SAHIN
  • Diagnosis and therapy of cancer involving cancer stem cells
    Patent number: 10604568
    Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 31, 2020
    Assignees: BioN Tech AG, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, Astellas Pharma Inc.
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
  • Monoclonal anti-GT 468 antibodies for treatment of cancer
    Patent number: 10596256
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 24, 2020
    Assignees: TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, ASTELLAS PHARMA INC.
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Rita Mitnacht-Kraus
  • Tumor vaccination involving a humoral immune response against self-proteins
    Patent number: 10526387
    Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 7, 2020
    Assignees: BIONTECH PROTEIN THERAPEUTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVRESITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
  • CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20190389920
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 26, 2019
    Inventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina Anna MROZ
  • BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES
    Publication number: 20190309067
    Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: September 20, 2017
    Publication date: October 10, 2019
    Inventors: Ugur Sahin, Christiane Stadler, Leyla Fischer, Arne Jendretzki, Özlem Türeci, Fabrice Le Gall, Maria Kreuzberg
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20190298803
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 3, 2019
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Genetic products differentially expressed in tumors and the use thereof
    Patent number: 10414824
    Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: September 17, 2019
    Assignee: GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Claudin-6-specific immunoreceptors and T cell epitopes
    Patent number: 10370423
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: August 6, 2019
    Assignees: Biotech Cell & Gene thrapies GMBH, Tron—Translationale Onkologie Ander Universitata tsmedizin Der Johannes Gutenberg-Universitat Main, Ganymed Pharmceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
    Patent number: 10314890
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 11, 2019
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
    Publication number: 20190169614
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Application
    Filed: February 13, 2019
    Publication date: June 6, 2019
    Inventors: Ugur Sahin, Özlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Woll, Gabriela-Elena Oprea
  • Identification of surface-associated antigens for tumor diagnosis and therapy
    Patent number: 10302647
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: May 28, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
  • Identification of tumor-associated markers for diagnosis and therapy
    Patent number: 10253373
    Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 9, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Antibodies for treatment of cancer expressing claudin 6
    Patent number: 10233253
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: March 19, 2019
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20190076525
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Application
    Filed: October 11, 2018
    Publication date: March 14, 2019
    Inventors: Ugur Sahin, Özlem Türeci
  • Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency
    Publication number: 20190062762
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Application
    Filed: September 27, 2018
    Publication date: February 28, 2019
    Applicant: BioNTech AG
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
    Publication number: 20190060430
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Application
    Filed: September 4, 2018
    Publication date: February 28, 2019
    Applicants: BioNTech Cell & Gene Therapies GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Agents for Treatment of Claudin Expressing Cancer Diseases
    Publication number: 20190055311
    Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 21, 2019
    Inventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6
    Publication number: 20190010244
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: January 10, 2019
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Monoclonal antibodies against claudin-18 for treatment of cancer
    Patent number: 10174104
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: January 8, 2019
    Assignee: GANYMED PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel